Disability and Rationing of Care amid COVID-19
By Katrina N. Jirik,
Bill of Health
| 04. 13. 2020
As medical professionals and bioethicists deal with the conundrum involved in establishing rationing of care guidelines, the mantra of the disability community comes to mind. Nothing about us, without us.
As health care resources grow increasingly scarce amid the COVID-19 pandemic, states, hospitals, and individuals are forced to make tough decisions about the rationing of care. These decisions are often framed in terms of medical and/or legal criteria. However, many people, especially the physicians who make the difficult decisions, realize they have a huge moral component related to perceptions of the value of an individual’s life.
Various states have triage guidelines in place, which differ somewhat, but primarily reflect a utilitarian goal of saving the most people with the least expenditure of finite resources. This is where the societal issue of the value of the life of a person with a disability comes into play.
Many of the guidelines state that the decision to treat needs to consider co-morbidities and anticipated resource use in the future. This is updated eugenic thought, whereby you have only the survival of the fittest, with an assumed understanding of what “the fittest” actually entails. These conceptions are based on a medical model of disability, something many people with disabilities find extremely problematic. It’s also...
Related Articles
By Samuelle Fajutrao Falk , The Conversation | 06.26.2026
When my colleagues and I asked autistic people and parents of autistic children in Sweden how they feel about genetic research in autism, one response stood out: “I hope genetic research finds new ways to help us, not erase us.”...
By Rebecca Simkin, BioNews | 06.29.2026
The US Food and Drug Administration (FDA) is allowing biotech company Regenxbio to reapply for licensing of a gene therapy for Hunter syndrome, in a reversal of its previous decision. Hunter syndrome, or mucopolysaccharidosis type II (MPS II), is a...
By Marisa Flook , BioNews | 06.29.2026
An anti-ageing gene therapy not approved by the US Food and Drug Administration (FDA) is set to be offered by an American company at overseas clinics outside of US jurisdiction.
The treatment, developed by Minicircle from Austin, Texas, uses a...
By Paul Knoepfler, Stat | 06.24.2026
What if you could precisely change the genome of a pre-implantation human embryo and then safely use that embryo to try to generate a healthier person? It’s a wild idea, but one that technology over the past decade has steadily...